铂-话题@MedSci

#铂#

382篇内容 | 6090人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1737765, encodeId=cb761e37765c8, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Immunother Cancer：复肿吴小华教授团队研究表明卡瑞利珠单抗联合法米替尼（famitinib）可作为铂类耐药复发卵巢癌治疗有效方案, objectType=article, longId=294001, objectId=19182940012d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19182940012d, replyNumber=0, likeNumber=65, createdTime=2022-03-28, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19182940012d, moduleTitle=J Immunother Cancer：复肿吴小华教授团队研究表明卡瑞利珠单抗联合法米替尼（famitinib）可作为铂类耐药复发卵巢癌治疗有效方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19182940012d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737756, encodeId=45561e3775671, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res：PARP抑制剂Pamiparib单药治疗铂敏感/耐药性卵巢癌的疗效, objectType=article, longId=221549, objectId=315622154982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=315622154982, replyNumber=0, likeNumber=98, createdTime=2022-07-01, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=315622154982, moduleTitle=Clin Cancer Res：PARP抑制剂Pamiparib单药治疗铂敏感/耐药性卵巢癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=315622154982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737781, encodeId=8b511e377817f, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Clin Oncol：二次细胞减灭术对铂敏感的复发性卵巢癌患者生存期的影响, objectType=article, longId=299554, objectId=e3252995544f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3252995544f, replyNumber=0, likeNumber=77, createdTime=2022-05-01, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3252995544f, moduleTitle=J Clin Oncol：二次细胞减灭术对铂敏感的复发性卵巢癌患者生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3252995544f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737784, encodeId=c64f1e377846d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Mol Cancer：新型生物标志物SNORD33可预测三阴性乳腺癌对铂类化疗敏感性, objectType=article, longId=300796, objectId=4279300e9651, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4279300e9651, replyNumber=0, likeNumber=126, createdTime=2022-03-16, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4279300e9651, moduleTitle=Mol Cancer：新型生物标志物SNORD33可预测三阴性乳腺癌对铂类化疗敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4279300e9651)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737766, encodeId=84471e3776637, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Front Oncol：顺铂联合伊立替康一线治疗转移性或不能切除的胸腺癌疗效显著耐受性好, objectType=article, longId=294107, objectId=35b729410e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35b729410e5b, replyNumber=0, likeNumber=94, createdTime=2022-09-09, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35b729410e5b, moduleTitle=Front Oncol：顺铂联合伊立替康一线治疗转移性或不能切除的胸腺癌疗效显著耐受性好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35b729410e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737739, encodeId=2e941e377395d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JCO：3期| 吉非替尼 vs 顺铂+长春瑞滨辅助治疗手术切除后的非小细胞肺癌的预后, objectType=article, longId=219788, objectId=61a2219e8811, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61a2219e8811, replyNumber=0, likeNumber=80, createdTime=2022-05-27, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61a2219e8811, moduleTitle=JCO：3期| 吉非替尼 vs 顺铂+长春瑞滨辅助治疗手术切除后的非小细胞肺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61a2219e8811)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2093017, encodeId=0184209301e00, content=<a href='/topic/show?id=bec09660687' target=_blank style='color:#2F92EE;'>#铜#</a>在人体蓄积可能会引发多种疾病，如<a href='/topic/show?id=abfb8150299' target=_blank style='color:#2F92EE;'>#肝豆状核变性#</a>等。但是，铜又是必不可少的。事实上，其它金属也如此，如<a href='/topic/show?id=9b3996e6940' target=_blank style='color:#2F92EE;'>#锰#</a>，<a href='/topic/show?id=49a9966213e' target=_blank style='color:#2F92EE;'>#铬#</a>，<a href='/topic/show?id=7b1696e06be' target=_blank style='color:#2F92EE;'>#锌#</a>，<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>，<a href='/topic/show?id=131b96625ae' target=_blank style='color:#2F92EE;'>#银#</a>等这些金属，无论是过多或过低，都是不可以的。过多了，会对特定的脏器形成损伤，也许将来，我们还会发现<a href='/topic/show?id=f45310493877' target=_blank style='color:#2F92EE;'>#锰死亡#</a>，<a href='/topic/show?id=6d94104939ad' target=_blank style='color:#2F92EE;'>#铬死亡#</a>，铂死亡等新的死亡现象。人类对于这些金属离子在人体内的作用，可能存在精确地调控作用。甚至，这些<a href='/topic/show?id=777a96182a1' target=_blank style='color:#2F92EE;'>#金属离子#</a>多与少，还能对人体正常功能起到关键的平稳作用。其次，这篇研究也为人类治疗<a href='/topic/show?id=2f1a104940f3' target=_blank style='color:#2F92EE;'>#铜代谢障碍疾病#</a>，如Menke病、肝豆状核变性（Wilson病）、CTR1缺陷等铜代谢障碍疾病带来新的治疗机遇。 <a href='/topic/show?id=8cdb1044e953' target=_blank style='color:#2F92EE;'>#铜死亡#</a>毕竟是全新的认知！, objectTitle=Science：细胞新的死亡方式——铜死亡被发现, objectType=article, longId=301149, objectId=8f61301149bc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220316/7ccbfece86ad42208f5ab5caa3896076.jpg, objectUrl=/article/show_article.do?id=8f61301149bc, replyNumber=0, likeNumber=200, createdTime=2022-10-11, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f61301149bc, moduleTitle=Science：细胞新的死亡方式——铜死亡被发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f61301149bc)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1737807, encodeId=ea021e3780731, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JAMA Oncol：依托泊苷 vs 伊立替康联合顺铂治疗消化系统晚期神经内分泌癌, objectType=article, longId=739500, objectId=4a5ee3950072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a5ee3950072, replyNumber=0, likeNumber=78, createdTime=2023-05-01, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a5ee3950072, moduleTitle=JAMA Oncol：依托泊苷 vs 伊立替康联合顺铂治疗消化系统晚期神经内分泌癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a5ee3950072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737770, encodeId=221c1e3777064, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性, objectType=article, longId=295133, objectId=e466295133ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e466295133ba, replyNumber=0, likeNumber=85, createdTime=2022-02-22, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e466295133ba, moduleTitle=Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e466295133ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737788, encodeId=69241e377881a, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效, objectType=article, longId=301524, objectId=dfda301524c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfda301524c5, replyNumber=0, likeNumber=95, createdTime=2022-12-27, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfda301524c5, moduleTitle=Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfda301524c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737763, encodeId=9a9c1e377639c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Cancer Res Clin Oncol：广医一院团队真实世界数据发现Sintilimab（信迪利单抗）联合紫杉醇+铂类或可进一步改善晚期肺鳞癌的生存, objectType=article, longId=292997, objectId=720229299ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=720229299ed0, replyNumber=0, likeNumber=69, createdTime=2022-03-23, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=720229299ed0, moduleTitle=J Cancer Res Clin Oncol：广医一院团队真实世界数据发现Sintilimab（信迪利单抗）联合紫杉醇+铂类或可进一步改善晚期肺鳞癌的生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=720229299ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737759, encodeId=0cd31e37759b6, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, objectType=article, longId=292260, objectId=b801292260d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b801292260d3, replyNumber=0, likeNumber=89, createdTime=2022-04-14, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b801292260d3, moduleTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b801292260d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737792, encodeId=ca9a1e377927b, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=AACR 2022：Adebrelimab或安慰剂加卡铂和依托泊苷作为广泛期SCLC的一线治疗, objectType=article, longId=724031, objectId=ca16e2403181, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca16e2403181, replyNumber=0, likeNumber=94, createdTime=2022-11-27, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca16e2403181, moduleTitle=AACR 2022：Adebrelimab或安慰剂加卡铂和依托泊苷作为广泛期SCLC的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca16e2403181)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737783, encodeId=82521e3778310, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Clin Oncol：JCOG1008研究表明高复发风险局部晚期头颈癌术后顺铂每周+放疗不劣效于顺铂三周方案, objectType=article, longId=300283, objectId=9daa30028368, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9daa30028368, replyNumber=0, likeNumber=83, createdTime=2022-04-13, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9daa30028368, moduleTitle=J Clin Oncol：JCOG1008研究表明高复发风险局部晚期头颈癌术后顺铂每周+放疗不劣效于顺铂三周方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9daa30028368)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737777, encodeId=76161e377777a, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, objectType=article, longId=295703, objectId=ea9c295e0337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea9c295e0337, replyNumber=0, likeNumber=83, createdTime=2022-08-30, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea9c295e0337, moduleTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea9c295e0337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737728, encodeId=06661e37728c5, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效, objectType=article, longId=217313, objectId=046121e3130e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=046121e3130e, replyNumber=0, likeNumber=88, createdTime=2022-07-22, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=046121e3130e, moduleTitle=J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=046121e3130e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737726, encodeId=0e311e37726c6, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果, objectType=article, longId=216406, objectId=13bc21640686, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13bc21640686, replyNumber=0, likeNumber=65, createdTime=2022-01-29, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13bc21640686, moduleTitle=J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13bc21640686)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737771, encodeId=d5431e37771f6, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性, objectType=article, longId=295185, objectId=293529518574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=293529518574, replyNumber=0, likeNumber=134, createdTime=2022-03-10, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=293529518574, moduleTitle=Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=293529518574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737745, encodeId=c8771e3774540, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=伊立替康联合奈达铂治疗复发耐药晚期上皮性卵巢癌的疗效研究, objectType=article, longId=220686, objectId=a17d220686e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a17d220686e6, replyNumber=0, likeNumber=62, createdTime=2022-08-31, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a17d220686e6, moduleTitle=伊立替康联合奈达铂治疗复发耐药晚期上皮性卵巢癌的疗效研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a17d220686e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737752, encodeId=a3281e377527c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Int J Cancer：Pazopanib +FLO (5-FU，奥沙利铂)一线治疗晚期胃癌患者的疗效和安全性：PaFLO研究, objectType=article, longId=221208, objectId=1c1e22120872, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c1e22120872, replyNumber=0, likeNumber=78, createdTime=2022-10-04, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c1e22120872, moduleTitle=Int J Cancer：Pazopanib +FLO (5-FU，奥沙利铂)一线治疗晚期胃癌患者的疗效和安全性：PaFLO研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c1e22120872)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

铂

2020-05-29

柳叶一刀 (审核中...)

前往app查看评论内容

#铂#

J Immunother Cancer：复肿吴小华教授团队研究表明卡瑞利珠单抗联合法米替尼（famitinib）可作为铂类耐药复发卵巢癌治疗有效方案

2022-03-28

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res：PARP抑制剂Pamiparib单药治疗铂敏感/耐药性卵巢癌的疗效

2022-07-01

仁者大医 (审核中...)

前往app查看评论内容

#铂#

J Clin Oncol：二次细胞减灭术对铂敏感的复发性卵巢癌患者生存期的影响

2022-05-01

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Mol Cancer：新型生物标志物SNORD33可预测三阴性乳腺癌对铂类化疗敏感性

2022-03-16

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Front Oncol：顺铂联合伊立替康一线治疗转移性或不能切除的胸腺癌疗效显著耐受性好

2022-09-09

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JCO：3期| 吉非替尼 vs 顺铂+长春瑞滨辅助治疗手术切除后的非小细胞肺癌的预后

2022-05-27

lifestar (审核中...)

前往app查看评论内容

全文收起 #铜#在人体蓄积可能会引发多种疾病，如#肝豆状核变性#等。但是，铜又是必不可少的。事实上，其它金属也如此，如#锰#，#铬#，#锌#，#铂#，#银#等这些金属，无论是过多或过低，都是不可以的。过多了，会对特定的脏器形成损伤，也许将来，我们还会发现#锰死亡#，#铬死亡#，铂死亡等新的死亡现象。人类对于这些金属离子在人体内的作用，可能存在精确地调控作用。甚至，这些#金属离子#多与少，还能对人体正常功能起到关键的平稳作用。其次，这篇研究也为人类治疗#铜代谢障碍疾病#，如Menke病、肝豆状核变性（Wilson病）、CTR1缺陷等铜代谢障碍疾病带来新的治疗机遇。 #铜死亡#毕竟是全新的认知！

Science：细胞新的死亡方式——铜死亡被发现

2022-10-11

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JAMA Oncol：依托泊苷 vs 伊立替康联合顺铂治疗消化系统晚期神经内分泌癌

2023-05-01

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性

2022-02-22

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Thorac Cancer：卡铂+白蛋白-紫杉醇联合治疗复发性小细胞肺癌（SCLC）的疗效

2022-12-27

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Cancer Res Clin Oncol：广医一院团队真实世界数据发现Sintilimab（信迪利单抗）联合紫杉醇+铂类或可进一步改善晚期肺鳞癌的生存

2022-03-23

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效

2022-04-14

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

AACR 2022：Adebrelimab或安慰剂加卡铂和依托泊苷作为广泛期SCLC的一线治疗

2022-11-27

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Clin Oncol：JCOG1008研究表明高复发风险局部晚期头颈癌术后顺铂每周+放疗不劣效于顺铂三周方案

2022-04-13

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效

2022-08-30

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效

2022-07-22

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

J Clin Oncol：Veliparib联合卡铂+紫杉醇化疗作为晚期肺鳞癌的一线治疗的效果

2022-01-29

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性

2022-03-10

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

伊立替康联合奈达铂治疗复发耐药晚期上皮性卵巢癌的疗效研究

2022-08-31

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Int J Cancer：Pazopanib +FLO (5-FU，奥沙利铂)一线治疗晚期胃癌患者的疗效和安全性：PaFLO研究

2022-10-04

科室
- - 订阅+
  - 更多科室
工具
服务